[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - Hofman, M S; Emmett, L; Sandhu, S; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (Lancet, 2021)
(10276):